If you're looking for exchange traded funds (ETFs) to buy, then you may want to look at the two listed below.
These exciting ETFs have recently been rated as buys. Here's what you need to know:
ETFS S&P Biotech ETF (ASX: CURE)
The first ETF to look at is the ETFS S&P Biotech ETF. This ETF provides investors with exposure to U.S. healthcare biotechnology companies. These are companies that are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering. This includes vaccine manufacturers and immunotherapy treatment developers.
Among its holding are promising biotechs such as Arrowhead Pharmaceuticals, Beam Therapeutics, Global Blood Therapeutics, and Twist Bioscience.
Felicity Thomas from Shaw and Partners is positive on the ETF. She recently told Livewire:
I'm going to go with a buy. Look I like to buy ETFs for the long term. We have an ageing population, and what's the most important thing in the world? Your health. Biotech, healthcare, and life sciences, that's where you want to be invested over the next couple of decades.
VanEck Vectors MSCI World ex Australia Quality ETF (ASX: QUAL)
Another ETF for investors to look at is the VanEck Vectors MSCI World ex Australia Quality ETF. It provides investors with access to a portfolio of high quality shares outside Australia that pass certain criteria.
Companies deemed to be high quality enough to be included in the fund are the likes of Apple, Mastercard, Microsfot, Nestle, Pfizer, and Visa.
Sarah Gonzales from Apt Wealth is a fan of the ETF. She also told Livewire:
My preferred ETF is the VanEck MSCI International Quality ETF. I think it provides exposure to that quality factor, which tends to outperform in market downturns. It does focus on factors like return and equity, year-on-year growth of earnings and also levels of debt. These are proxies for profitability, earnings variability, and the level of debt of companies. Particularly if we are going into a recession, I think these are really the factors that I think we should focus on.
